Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | CASP7 | P55210 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.33 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 3/20 | 0.31 |
| ▸ | EP300 | Q09472 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1600166 | 0.70 | CREBBP (0.40) | MEN1GAAMAPTALOX15CASP1 | |
| SCHEMBL17376745 | 0.64 | CREBBP (0.42) | MEN1GAAMAPTALOX15CASP1 | |
| SCHEMBL20739437 | 0.62 | MEN1 (0.37) | MEN1GAAMAPTALOX15CASP1 | |
| Naphthalene SCHEMBL56790 | 0.60 | CYP2A6 (0.61) | MEN1MAPTALOX15KMT2A | |
| SCHEMBL13949315 | 0.60 | MAPT (0.43) | MEN1GAAMAPTALOX15CASP1 | |
| SCHEMBL5458130 | 0.60 | IDO1 (0.46) | MEN1GAAMAPTALOX15CASP1 | |
| SCHEMBL4265282 | 0.60 | CREBBP (0.39) | MEN1GAAMAPTALOX15CASP1 | |
| SCHEMBL9718691 | 0.60 | CREBBP (0.39) | MEN1GAAMAPTALOX15CASP1 | |
| SCHEMBL3319641 | 0.60 | CREBBP (0.39) | MEN1GAAMAPTALOX15CASP1 | |
| SCHEMBL6587899 | 0.60 | CREBBP (0.50) | MEN1GAAMAPTALOX15CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050256122-A1 | Substituted pyridazinones | PHARMACIA CORPORATION | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256122-A1 | Substituted pyridazinones | MAP4K2, MAPK6, MAP3K6 | MEN1 4492/4885GAA 956/4885MAPT 1544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.